Development of a Pan-Cancer 15 Gene Expression Signature to Detect a Subgroup Driven by MAPK Signalling
Download Almac Diagnostic Services Poster Presentation on ‘Development of a Pan-Cancer 15 Gene Expression Signature to Detect a Subgroup Driven by MAPK Signalling’.
- A 15 gene signature has been developed from formalin fixed paraffin embedded samples to detect a molecular subgroup driven by MAPK/EMT signalling across multiple diseases .
- This assay predicts sensitivity to MEK inhibitors in preclinical model systems.
- Further work aims to validate the EMT assay in clinical samples from patients treated with a MEK or EMT inhibitor.
- This assay may be helpful for clinical trial enrichment to select patients that are likely to benefit from MAPK or EMT targeted therapies.
Your global partner for biomarker discovery, development & commercialisation.
We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.
Clinical Trial Assays
Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.
A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.